Important Information

Similar documents
Important Information

A look at Marijuana in 2014

Substance Use Disorders

POLICY NUMBER: POL 153

Consumer Information Cannabis (Marihuana, marijuana)

Common Diagnosis Codes and Tips for Coding Nicotine Use/

Opioid Use Issues: All the Players

Cannabinoids (CB): Outline. CB: Epidemiology. CB: Categorization. CB: Pharmacodynamics. Part #1: Cannabinoid (CB) Primer.

INITIAL PATIENT INTAKE FORM

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی

Chapter 7. Screening and Assessment

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

A new model for prescribing varenicline

CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Alcohol Misuse Clinical Pathway Outline

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

Marijuana in the Obstetric Population

Controlled Substance and Wellness Agreement

Addiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine

Legalized Marijuana: Uses, Misuses & Abuses. Disclosures. Objectives. Kennon Heard University of Colorado SOM Dept Of Emergency Medicine

Cannabis for Medical Purposes

Acute General Medical and Surgical Admission:

Cannabinoids: access and symptom management in cancer

Marijuana. Marijuana (Cannabis Use Disorder) Learning Goals/Objectives

Medical Marijuana Consent Form

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

The Role of the PDMP: Foundational Knowledge and Best Practices

PATIENT QUESTIONNAIRE

PATIENT INTAKE FORM. Name: Address: Town: State: Zip Code: MMJ Card #: Exp. Date: Drivers License #: Exp. Date: Home Phone: Cell:

How does cannabis affect my work performance?

Opiate Use Disorder and Opiate Overdose

Clinical Evaluation: Assessment Goals

Neurobiology of Drug Abuse and Addiction PSYC 450

Objectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access

Do I Have a Drinking Problem?

Medicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose

Tapering Opioids Best Practices*

UNDERSTANDING TEENAGE DRUG USE. Dr DES CORRIGAN Sligo Oct 13 th 2012

Module Three Screening and Assessment V

Appendix F Federation of State Medical Boards

SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION

March 29, 2017 Debra K. Smith, Ph.D. St. Charles Hospital Port Jefferson, New York

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Marijuana and the Chronic Non-Cancer Pain Patient

Proposed Revision to Med (i)

Is cannabis addictive? CANNABIS EVIDENCE BRIEF

PATIENT GROUP DIRECTION

Essential Shared Care Agreement Naltrexone

2016 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older)

I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people

SMOKING CESSATION IS HARD

2/21/2018. What are Opioids?

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2

CERTIFICATION AND AUTHORIZATION (if applicable)

Section I. Short-acting opioid Prior Authorization Criteria

EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO

Classification of Abuse-Related Events in Analgesic Clinical Trials: Recommendations and Research Agenda

These documents were created to support the work of the Coalition of Colorado Campus Alcohol and Drug Educators. We welcome prevention teams at

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

History of Present Illness (HPI) Assessment and Plan Template

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH

ONLINE EDITION DAYS 17-21

Depression in the Eldery Handout Package

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists

Trends, Tactics and Toxicity: Marijuana Movement on Missouri College Campuses. Janice Putnam PhD, RN Amy Kiger MS, ABD Kelly Skinner DNP, FNP-C

THE ADDICTIVE BRAIN SC 212 JANUARY 3, 2017 JOHN BUSH

CDHA 2016 Fall Symposium. Speaker Handout Files. For registered attendees only

PSYCHOPATHOLOGY, DIFFERENTIAL DIAGNOSIS, AND THE DSM-5: A COMPREHENSIVE OVERVIEW

PATIENT QUESTIONNAIRE

Survey of Temporary Assistance For Needy Families (TANF) Recipients

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Updated: 08/2017 DMMA Approved: 11/2017

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Overview of Psychoactive Drug use

Welcome to MedWell. Patient Information. Name: Address: City: State: Zip Code: !Other. Name: Address: City: State:

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012

The Effects known & unknown of Marijuana in Older Adults. Danielle Fixen, PharmD, BCGP, BCPS University of Colorado School of Pharmacy

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

NBPDP Drug Utilization Review Process Update

KAP Keys. For Clinicians. Based on TIP 24 A Guide to Substance Abuse Services for Primary Care Clinicians. CSAT s Knowledge Application Program

Medical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

10 Questions to Ask. Before You Use Marijuana

PATIENT QUESTIONNAIRE

Brighton and Hove Pharmacy Enhanced Service (PLES 02)

HD CLINIC MEDICAL HISTORY FORM

Psychosis, Mood, and Personality: A Clinical Perspective

Hot Topics in Addiction Medicine. Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017

Medical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University

Clinical and public health significance of the proposed changes to the diagnosis of alcohol abuse and dependence in DSM-5

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

Home Phone Cell Phone

Patient Assessment Form

Transcription:

Important Information Please work through the following pages with your patient or the patient s chart as necessary. Fax completed documents to 1 888 629-4722. Keep the original in your chart / file. Fee: upon receiving the completed booklet, WorkSafeNB will pay the booklet completion fee equivalent to twice the amount of an office visit fee. Each section must be complete to qualify for reimbursement by WorkSafeNB. If you do not wish or are unable to complete the booklet and wish to stop after question 1, please submit this completed receipt and pg. 1 of the WorkSafeNB Cannabis Review Booklet and WorkSafeNB will pay the administration fee equivalent to 33% of an office visit fee. THIS DOCUMENT IS YOUR RECEIPT. I, request full reimbursement for completing the Cannabis Review booklet for my patient,. I, decline to complete the Cannabis Review Booklet for my patient,. I have completed the administrative questions on the first page of the booklet and am requesting the appropriate reimbursement for administrative fees. Authorizing (Prescribing) Physician name: Signature: Date: Payee Code: For QUESTIONS on completing this form please contact WorkSafeNB toll-free at 1 877 647-0777. Please note: The information requested is based upon a reasonable standard of medical practice in the province of New Brunswick. The review process was developed according to the guidelines of WorkSafeNB s Cannabis (Marijuana) for Medical Purposes policy, available online at worksafenb.ca/info/cannabis-policy.

WorkSafeNB Cannabis Review Booklet (Physician Form Full Risk Assessment) AUTHORIZING (PRESCRIBING) PHYSICIAN This patient s treating physician was unable or unwilling to provide the required supporting information regarding medical authorization of cannabis products. Please provide the following information: PATIENT INFORMATION Patient name: Date of birth: Address: Phone number: Claim number: 1. Do you wish to participate in WorkSafeNB s Cannabis Review Process by completing this document? : PROCEED TO QUESTION 2. : I recognize WorkSafeNB may conduct an independent medical evaluation to complete the assessment. STOP HERE. SUBMIT INVOICE FOR 33% OF AN OFFICE VISIT FEE. Copyright protected 2018 1 of 10

2. What are the patient s specific symptoms for which medical authorization for cannabis is being requested (nature and location of symptoms)? 3. To your knowledge, when did the symptoms begin (YYYY-MM-DD)? 4. What is the working diagnosis responsible for your patient s symptoms? 5. How do you think your patient s symptoms impact his or her functioning in occupational and daily activities? 6. Please list therapies trialed to date for your patient s symptoms and condition(s) identified above: Medications trialed (non-cannabinoid) (attach another page if necessary) Name of drug i. Initiation date Maximum dosage achieved Beneficial effects Adverse effects Reason for discontinuation (if applicable) Date discontinued Copyright protected 2018 Page 2 of 10

i iv. v. 7. To your knowledge, has your patient tried any pharmaceutical cannabinoid for the above symptom(s) or condition(s), such as nabilone, nabiximols or other synthetic cannabinoid product? Please include the initiation date, maximum dosage achieved, main effects, side effects, reasons for discontinuation, and date of discontinuation if applicable. Pharmaceutical Cannabinoids Trialed Name of cannabinoid i. Initiation date Maximum dosage achieved Beneficial effects Adverse effects Reason for discontinuation (if applicable) Date discontinued i iv. Copyright protected 2018 Page 3 of 10

8. Please list all current medications that you know to be prescribed or otherwise medically authorized for your patient, and include the dosage, schedule and indicated condition. (Please attach another page if more space is required) All Current Medications Name of drug Dosage Schedule Indicated condition i. i iv. v. 9. To your knowledge, was your patient using cannabis prior to the work injury or onset of the condition for which he or she has a WorkSafeNB claim? UNKWN Copyright protected 2018 Page 4 of 10

10. The following information is necessary for risk assessment or potential contraindications. Please list ALL past and current medical conditions of which you are aware for this patient. (Please attach another page if more space is required) 11. The following information is necessary for risk assessment or potential contraindications. Please list ALL prior surgeries or procedures of which you are aware for this patient. (Please attach another page if more space is required) 12. The following information is necessary for risk assessment or potential contraindications. Please list ALL current and past psychological/psychiatric conditions of which you are aware for this patient. (Please attach another page if more space is required) Copyright protected 2018 Page 5 of 10

13. The following information is necessary for risk assessment or potential contraindications. Please list ALL abnormal physical findings on current examination, whether related or unrelated to the work injury or condition. Please include any pain or neuropathic findings. (Please attach another page if more space is required) 14. Does your patient smoke tobacco? UNKWN If, please provide the amount he or she uses per day to the best of your knowledge, as well as how many years he or she has been a regular tobacco user: 15. Does your patient consume alcohol? If, please provide the amount he or she uses per day to the best of your knowledge, as well as how many years he or she has been a regular drinker: 16. To your knowledge, does your patient currently use recreational drugs other than cannabis? UNKWN If, please provide the type(s) of drug that he or she uses and the amount(s) per day to the best of your knowledge, as well as how many years he or she has been a regular substance user: Copyright protected 2018 Page 6 of 10

17. To the best of your knowledge, does your patient have a history of substance use disorder involving a drug other than cannabis? If, which substance(s) and describe or give a brief summary. UNKWN 18. If your patient does not use cannabis, please proceed to Question 19. If your patient uses cannabis, please respond to the following statements to the best of your knowledge. If unknown, leave the question blank. My patient: i. Takes cannabis in larger amounts or over a longer period than was intended. i iv. Has persistent desire or unsuccessful efforts to cut down or control cannabis use. Spends a great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects. Demonstrates a craving, or a strong desire or urge to use cannabis v. Uses cannabis despite it resulting in a failure to fulfill major role obligations at work, school, or home. vi. v Uses cannabis despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis. Gives up or reduces important social, occupational, or recreational activities because of cannabis use. vi Uses cannabis in situations where it is physically hazardous. ix. Continues using cannabis despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis. x. Does your patient show signs of tolerance, as defined by either of the following: A need for markedly increased amounts of cannabis to achieve intoxication or desired effect. Copyright protected 2018 Page 7 of 10

Markedly diminished effect with continued use of the same amount of cannabis. xi. Does your patient show signs of withdrawal, as manifested by either of the following: Three (or more) of the following signs and symptoms develop within approximately one week after cessation of cannabis use (heavy and prolonged: usually daily or almost daily use): Irritability, anger, or aggression; nervousness or anxiety; sleep difficulty (e.g. insomnia, disturbing dreams); decreased appetite or weight loss; restlessness; depressed mood; at least one of the following physical symptoms causing significant discomfort: abdominal pain, shakiness/tremors, sweating, fever, chills, or headache. 19. Does the following apply to your patient to the best of your knowledge? If unknown, leave the question blank. i. They are under the age of 25 They have a personal history or strong family history of psychosis i They have a current or past cannabis use disorder iv. They have an active substance use disorder v. They have cardiovascular disease (angina, peripheral vascular disease, cerebrovascular disease, arrhythmias) vi. They have respiratory disease v She is a woman who is pregnant, planning to become pregnant, or breastfeeding vi They have a concurrent active mood or anxiety disorder ix. They smoke tobacco x. They have risk factors for cardiovascular disease xi. They are a heavy user of alcohol or is taking high doses of opioids, benzodiazepines or other sedating medications, whether prescribed or available over the counter Copyright protected 2018 Page 8 of 10

20. In your opinion, does your patient require additional assessment and/or support for psychological condition(s), including issues related to substance misuse? If, please elaborate. 21. Do you have any concerns for your patient regarding side effects and/or adverse events associated with cannabis use (Check one answer for each selection)? RISKS NE SOME UNSURE Unable to evaluate Medical/psychological side effects Cannabis dependence Driving impairment Ability to perform or function at work Ability to meet work site safety standards tasks 22. What are the specific functional goals of treatment using cannabis? Copyright protected 2018 Page 9 of 10

23. Please specify details of the medicinal cannabis authorization (if already provided): a. This patient has medical authorization for / (amount/units) of cannabis product per day for duration. b. Mode(s) of administration: c. Document reported strain/ oil name/ other product name below: i. Strain/ product name % THC % CBD i d. Cannabis brand or identifier: e. Licensed producer name: Copyright protected 2018 Page 10 of 10